Dose related growth response to indometacin in Gitelman syndrome.
Growth failure is a recognised feature of Gitelman syndrome, although it is not as frequent as in Bartter syndrome. Indometacin is reported to improve growth in Bartter syndrome, but not in Gitelman syndrome, where magnesium supplements are recommended. This paper presents 3 sisters with Gitelman syndrome who could not tolerate magnesium supplements, and whose hypotension and polyuria were eliminated by taking 2 mg/kg/day indometacin, but who grew poorly. However, increasing the indometacin dose to 4 mg/kg/day improved their growth significantly, without changing their symptoms or biochemistry. Gastrointestinal haemorrhage necessitated the use of misoprostol.
Liaw
L C
LC
Department of Paediatric Nephrology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.
Banerjee
K
K
Coulthard
M G
MG
D001477:Bartter Syndrome; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy; D007213:Indomethacin / Q000627:therapeutic use*; D007223:Infant; D008274:Magnesium / Q000009:adverse effects; D011141:Polyuria / Q000188:drug therapy; D013577:Syndrome
D016861:Cyclooxygenase Inhibitors; D008274:Magnesium; D007213:Indomethacin